ArticleApplied microbiology and biotechnology2026
Quantitative proteomics identifies GntR as a novel potential DIVA antigen for bovine brucellosis.
Article in Applied microbiology and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Brucella is a zoonotic pathogen causing brucellosis. Current serological tests cannot differentiate infected from vaccinated animals (DIVA) due to antibody interference from live vaccines. This study used parallel accumulation-serial fragmentation (PASEF)-based quantitative proteomics to compare virulent S2308 and vaccine A19 strains of Brucella abortus. Among 2,131 identified proteins, 302 were differentially expressed, including 43 and 32 proteins exclusive to S2308 and A19, respectively. Bioinformatic analysis showed enrichment in metabolic and transport functions. The transcriptional regulator GntR family (GntR), with significantly high expression in S2308, was selected as a DIVA candidate antigen. Reverse transcription quantitative real-time PCR (RT-qPCR) and western blot confirmed significantly higher GntR transcription and expression in S2308 during logarithmic growth. Serological validation indicated stronger reactivity of GntR with sera from wild strain-infected cattle than from A19 vaccinated or negative cattle. An indirect enzyme-linked immunosorbent assay (iELISA) based on GntR was established and showed high sensitivity and specificity, consistent with standard bovine brucellosis diagnostics. Dynamic monitoring in a mouse model revealed that iELISA enabled DIVA differentiation from 0 to 21 days post-infection. Thus, GntR is a novel potential DIVA antigen, providing a robust serological tool to distinguish B. abortus wild strain infection from A19 vaccination in cattle. KEY POINTS: • PASEF-based quantitative proteomics to compare proteomic profiles of B. abortus S2308 and A19. • GntR transcription and expression are higher in Brucella S2308 than in A19 during logarithmic growth. • A novel potential DIVA antigen GntR was identified for bovine brucellosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.